A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

NCT01562899 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

77

Enrollment

INDUSTRY

Sponsor class

Stopped Study was withdrawn due to scientific and business considerations.

Conditions

Metastatic Pancreatic Adenocarcinoma
BRAF Mutated Melanoma

Interventions

DRUG: MEK162
DRUG: AMG 479

Sponsor

Pfizer